Seres Therapeutics, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Seres Therapeutics, Inc. (MCRB) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$36.60 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-05
- Seres Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$15.93M, a 156.79% decline year-over-year.
- Seres Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was $28.06M.
- Seres Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$16.54M.
- Seres Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$68.19M.
- Seres Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $14.97M.
- Seres Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$96.69M.
- Seres Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$35.07M.
- Seres Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$16.79M, a 123.33% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$36.60M 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | -$15.93M 10-Q · filed 2026-05-05 | |||
| 2025-12-31 | $14.97M 10-K · filed 2026-03-12 | |||
| 2025-09-30 | $16.84M 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | $14.59M 10-Q · filed 2026-08-05 | |||
| 2025-03-31 | $28.06M 10-Q · filed 2026-05-05 | |||
| 2024-12-31 | -$96.69M 10-K · filed 2026-03-12 | |||
| 2024-09-30 | -$59.45M 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | -$55.05M 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | -$16.54M 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | -$35.07M 10-K · filed 2026-03-12 | |||
| 2023-09-30 | $6.88M 10-Q · filed 2024-11-13 | |||
| 2023-06-30 | $66.49M 10-Q · filed 2024-08-13 | |||
| 2023-03-31 | -$68.19M 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | -$16.79M 10-K · filed 2025-03-13 | |||
| 2022-09-30 | $25.58M 10-Q · filed 2023-11-02 | |||
| 2021-12-31 | $71.95M 10-K · filed 2024-03-05 | |||
| 2020-12-31 | $50.92M 10-K · filed 2023-03-07 | |||
| 2019-12-31 | -$20.81M 10-K · filed 2022-03-01 | |||
| 2018-03-31 | $11.11M 10-Q · filed 2018-05-09 | |||
| 2017-03-31 | -$12.64M 10-Q · filed 2018-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |